Could this drug help patients with Hard-to-Treat breast cancer?

NCT ID NCT06750484

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 40 adults with advanced breast cancer that has no HER2 protein (HER2-0). Participants get the drug every 3 weeks. The goal is to see if it shrinks tumors and which patients benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (T-DXd)
What this could lead to: If successful, this could offer a new treatment option for people with HER2-0 advanced breast cancer who have few alternatives.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The drug can cause serious side effects like lung inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER, METASTATIC

Contacts and locations

Show contact details

Locations

Emory Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
University of Rochester Medical Center
RECRUITING

Rochester, New York, 14642, United States

Contact Email: •••••@•••••
Yale University
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.